UM
Residential Collegefalse
Status已發表Published
The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy
Wu X.1; Feng Q.-M.1; Wang Y.2; Shi J.1; Ge H.-L.2; Di W.1
2010-02-01
Source PublicationCancer Immunology, Immunotherapy
ISSN03407004 14320851
Volume59Issue:2Pages:279-291
Abstract

Till now, little is known about the effects of chemotherapy on the immunity of cancer patients and the ideal timing ("window" period) for immunotherapy combined with chemotherapy. In this study, we addressed the immunogenicity of apoptotic ovarian cancer cells induced by paclitaxel and carboplatin, the immunologic aspects in ovarian cancer patients under chemotherapy, and the CTL response when CD8 T cells were stimulated with tumor antigen in the "window" period. The immunogenicity of apoptotic ovarian cancer cells was detected first. Then, blood samples from each ovarian cancer patient were obtained before (S) and at days 5-7 (S), days 12-14 (S) and days 25-28 (S) after chemotherapy. The proportions of immunocyte subsets and the function of NK cells were studied. We found that apoptotic ovarian cancer cells elicited a powerful CTL response with antitumor activity in vitro. The proportions of CD3 T cells, CD4 T cells and the ratio of CD4 to CD8 cells did not change significantly on S , S and S, compared to S, whereas the percentage of Treg cells decreased remarkably on S. The proportions of Th1, Tc1, CD45RO memory T, NKT cells and the ratio of Tc1 to Tc2 cells increased significantly on S. IFN-γ secreting CD8 T cells also increased remarkably on S, especially when CD8 T cells were stimulated with autologous tumor antigen. From our point of view, chemotherapy induces temporary immune reconstitution and augments anti-tumor immune response. It is probable that the "window" period of days 12-14 after chemotherapy provides the best opportunity for immunotherapy. © 2009 Springer-Verlag.

KeywordApoptosis Chemotherapy Immune Reconstitution Immunogenicity Ovarian Cancer
DOI10.1007/s00262-009-0749-9
URLView the original
Language英語English
WOS IDWOS:000271748600010
Scopus ID2-s2.0-71849088755
Fulltext Access
Citation statistics
Document TypeJournal article
CollectionUniversity of Macau
Affiliation1.Renji Hospital
2.Shanghai Jiao Tong University
Recommended Citation
GB/T 7714
Wu X.,Feng Q.-M.,Wang Y.,et al. The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy[J]. Cancer Immunology, Immunotherapy, 2010, 59(2), 279-291.
APA Wu X.., Feng Q.-M.., Wang Y.., Shi J.., Ge H.-L.., & Di W. (2010). The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. Cancer Immunology, Immunotherapy, 59(2), 279-291.
MLA Wu X.,et al."The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy".Cancer Immunology, Immunotherapy 59.2(2010):279-291.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Wu X.]'s Articles
[Feng Q.-M.]'s Articles
[Wang Y.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Wu X.]'s Articles
[Feng Q.-M.]'s Articles
[Wang Y.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Wu X.]'s Articles
[Feng Q.-M.]'s Articles
[Wang Y.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.